Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
May 27 2021 - 4:30PM
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced the
publication of preclinical data of CY6463 in Frontiers in
Pharmacology. Cyclerion is developing CY6463, an oral,
first-in-class, central nervous system (CNS)-penetrant sGC
stimulator, for neurological diseases associated with cognitive
impairment, including Alzheimer's disease with vascular pathology
(ADv), Mitochondrial Encephalomyopathy, Lactic Acidosis and
Stroke-like episodes (MELAS), as well as Cognitive Impairment
Associated with Schizophrenia (CIAS).
Cyclerion identified and developed CY6463 based
on its ability to readily access the CNS and amplify nitric
oxide‐soluble guanylate cyclase‐cyclic guanosine monophosphate
(NO-sGC-cGMP) signaling in the brain. CY6463 was designed to
address multiple pathophysiological features of neurodegenerative
and neuropsychiatric diseases associated with cognitive
impairment.
Extensive preclinical data from CY6463 and
decades of research validate the crucial role of the sGC pathway in
brain physiology and cognition. Across a range of preclinical
models, administration of CY6463 resulted in physiologically
relevant drug levels in cerebrospinal fluid (CSF) and led to
improvements in neuronal function, neuroprotection, and cognitive
performance. Together, these data further support the clinical
development of CY6463 as a novel and potentially paradigm-shifting
approach to the treatment of neurodegenerative and neuropsychiatric
disorders.
Results from initial CY6463 clinical studies
have demonstrated favorable safety and tolerability and
pharmacologically relevant exposure in the CSF. In addition, CY6463
resulted in promising impacts on brain cortical oscillations,
neuroinflammation, and other neurophysiological measures that
support continued clinical development.
Cyclerion has an active Phase 2 study of CY6463
in participants with MELAS and the Company is planning to initiate
additional Phase 2 studies in individuals with ADv and CIAS.
About Cyclerion
Therapeutics Cyclerion Therapeutics is a
clinical-stage biopharmaceutical company on a mission to develop
treatments that restore cognitive function. Cyclerion is advancing
novel, first-in-class, CNS-penetrant, sGC stimulators that modulate
a key node in a fundamental CNS signaling pathway. The
multidimensional pharmacology elicited by the stimulation of sGC
has the potential to impact a broad range of CNS diseases. The most
advanced compound, CY6463, has shown rapid improvement in
biomarkers associated with cognitive function and is currently in
clinical development for Alzheimer's Disease with Vascular
pathology (ADv), Mitochondrial Encephalomyopathy, Lactic Acidosis
and Stroke-like episodes (MELAS), and Cognitive Impairment
Associated with Schizophrenia (CIAS). Cyclerion is also advancing
CY3018, a next-generation sGC stimulator.
For more information about Cyclerion, please
visit https://www.cyclerion.com/ and follow us on Twitter
(@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).
Forward Looking StatementThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Our
forward-looking statements are based on current beliefs and
expectations of our management team that involve risks, potential
changes in circumstances, assumptions, and uncertainties. We may,
in some cases use terms such as “predicts,” “believes,”
“potential,” “continue,” “anticipates,” “estimates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “likely,” “will,”
“should” or other words that convey uncertainty of the future
events or outcomes to identify these forward-looking statements.
Each forward-looking statement is subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statement. Applicable risks
and uncertainties include the risks listed under the heading “Risk
Factors” and elsewhere in our 2020 Form 10-K filed on February
25, 2021, and our subsequent SEC filings including the Form 10-Q
filed on April 30, 2021. Investors are cautioned not to place undue
reliance on these forward-looking statements. These forward-looking
statements (except as otherwise noted) speak only as of the date of
this press release, and Cyclerion undertakes no obligation to
update these forward-looking statements, except as required by
law.
InvestorsCarlo Tanzi, Ph.D.Kendall Investor
Relationsctanzi@kendallir.com
MediaAmanda SellersVerge Scientific
Communicationsasellers@vergescientific.com
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Apr 2023 to Apr 2024